Bicycletx Limited

Steven Stanway

Michael Skynner

Ellen Gowans

Gemma Elizabeth Mudd

Liuhong Chen

Katerine Van Rietschoten

Michael Rigby

Amy Brown

Punit Seth

John Davis

Liudvikas Urbonas

Donatella Di Rienzo

Rama McCrory

Tom Smith

Yuliya Demydchuk

Emma Murphy

Emma Mead

Paul Brennan

Mike Rigby

The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which bind to TfR1. The invention also relates to multimeric binding complexes which comprise at least two of said bicyclic peptide ligands. The invention also includes pharmaceutical compositions comprising said peptide ligands and multimeric binding complexes and the use of said peptide ligands, and multimeric binding complexes and pharmaceutical compositions in preventing, suppressing or treating a disease or disorder through TfR1 mediated delivery of a therapeutic agent.

Bicyclic peptide ligands specific for transferrin receptor 1 (TfR1)

The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which bind to TREM2. The invention also relates to multimeric binding complexes which comprise at least two of said bicyclic peptide ligands. The invention also includes pharmaceutical compositions comprising said peptide ligands and multimeric binding complexes and the use of said peptide ligands, multimeric binding complexes and pharmaceutical compositions in preventing, suppressing or treating a disease or disorder mediated by TREM2.

Bicyclic peptide ligands specific for TREM2

Growing community of inventors

Cambridge, United Kingdom

Steven Stanway